|
|
|
|
|
|
Sponsors and Collaborators: |
University of British Columbia GlaxoSmithKline Canadian HIV Trials Network |
Information provided by: | University of British Columbia |
ClinicalTrials.gov Identifier: | NCT00143702 |
The purpose of this study is to determine the best way to treat people on d4T (stavudine) with high levels of lactic acid. Switching from d4T to abacavir will be assessed. Adding riboflavin and thiamine will also be assessed.
Participants will be randomly assigned to one of four groups:
The study plans to involve eighty participants from Canada and Argentina for a treatment period of 16 weeks and a follow-up visit at week 24.
Condition | Intervention | Phase |
Acidosis, Lactic |
Drug: d4T Drug: Abacavir Drug: Riboflavin and Thiamine (Supplementation) |
Phase II Phase III |
MedlinePlus related topics: | AIDS |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment |
Official Title: | Randomized, Open-Label Study of Continued Stavudine Versus Abacavir Substitution With or Without Riboflavin and Thiamine Supplementation in HIV-Infected Patients Who Have Elevated Venous Lactic Acid While on Stavudine-Based Therapy (DAVE) |
Estimated Enrollment: | 80 |
Study Start Date: | August 2001 |
Study Completion Date: | August 2006 |
Primary Completion Date: | August 2006 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, British Columbia | |||||
St. Paul's Hospital | |||||
Vancouver, British Columbia, Canada, V6Z 1Y6 | |||||
Canada, Ontario | |||||
Positive Care Clinic | |||||
Toronto, Ontario, Canada |
University of British Columbia |
GlaxoSmithKline |
Canadian HIV Trials Network |
Principal Investigator: | Julio Montaner, MD | University of British Columbia |
Related Info 
  |
Responsible Party: | University of British Columbia ( Dr. Julio Montaner ) |
Study ID Numbers: | P00-0159, CTN 169 |
First Received: | August 31, 2005 |
Last Updated: | September 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00143702 |
Health Authority: | Canada: Health Canada |
|
|
|
|
|